Shanmugam Muthusamy's Form 4 filing
Ani Pharmaceuticals Inc (ANIP) · filed Jun 24, 2024
- Accession no.
- 0001870913-24-000024
- Filed
- Jun 24, 2024
- Trade date
- Jun 21, 2024
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $1.18M. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Shanmugam MuthusamyCIK 0001870913 | Director, Officer (HEAD OF R&D, COO-NOVITIUM OPS) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 21, 2024 | Common Stock | SSaleDisposed | −20,000 | $58.90F2 | −$1,178,000 | 682,620 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The shares were sold in multiple trades at prices ranging from $58.43 to $59.48. The price reported above reflects the weighted average sales price.
Referenced by the price of 1 transaction in Table I.